I'm not aware of any significant findings supporting Ivermectin in treating COVID. It appears there were 1 or more studies that showed in vitro (using cell cultures) benefits against SARS-COV and similar viruses when using extremely high doses (well above what could be safely administered to humans). This seems to be were the idea came from, but again it just doesn't work as a clinical treatment of COVID.
I'm not knocking you DawgWCK, just laying out what I know. I'm not a virologist, but I have worked on viral resistance in marine organisms so I'm not a complete novice. Also, the media and media-acting mouth pieces often misinterpret research findings and/or overstate them. Once this happens, the general public/social media pervert the findings even more. It is like a fishing tale where the bass started out as 7 lbs and ended up 17 lbs.
Here is what I have seen:
"• The current study by Caly et al. was published as a “pre-proof”, which means it is still subject to additional edits. The main outcome of the study was reduction in virus detected in cell culture at 48 hours, and ivermectin did result in a 50% reduction in virus.
• The authors report promising “in vitro” anti-viral activity of ivermectin against SARS-CoV2, however, it is uncertain whether or not the plasma concentration required to emulate these in vitro exposures can be safely achieved in humans. The concentration used in the study by Caly et al. was approximately 50-fold greater than concentrations achieved with current clinical regimens.
•
The authors do not recommend ivermectin as a safe and effective treatment option for COVID-19, but rather call for in vivo research to further explore their preliminary findings.
•
Prior “in vitro” studies demonstrated promising anti-viral activity of ivermectin for Dengue virus, which is also a single-stranded RNA virus, but further “in vivo” trials have shown no clinical benefits in humans. 2-3
•
Ivermectin is associated with significant side effects, including Mazzotti reaction (dermatological reaction including pruritis and urticaria), lymphadenitis, and arthralgias. In addition, ivermectin can cross the blood-brain barrier and induce encephalopathy, especially in patients in hyperinflammatory states such as COVID-19. 4
•
To date, no clinical trials have demonstrated the safety and efficacy of ivermectin for treatment or prevention of COVID-19 infection.
and,
DURHAM, N.C. – A study led by the
Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.
“There was no significant benefit in our primary endpoint of resolution of symptoms in mild-to-moderate COVID-19 illness,” said
Adrian Hernandez, M.D., the study’s administrative principal investigator and executive director of the DCRI. “Overall, most people improved their symptoms whether they took ivermectin or not. Given these results, there does not appear to be a role for ivermectin outside of a clinical trial setting, especially considering other available options with proven reduction in hospitalizations and death.”
There was also no difference observed in the number of hospitalizations or emergency room visits. Findings appear on
medRxiv, a pre-publication server, and have been submitted to a peer-reviewed journal.
DURHAM, N.C. – A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.
corporate.dukehealth.org